Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
17 July 2023Website:
http://sagimet.comNext earnings report:
21 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 22:04:53 GMTDividend
Analysts recommendations
Institutional Ownership
SGMT Latest News
Dr. Scott Friedman will discuss the unmet need in MASH and present Sagimet's topline data from the FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH.
SAN MATEO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways, today announced that management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual NASH Investor Conference on Tuesday, October 24, 2023, at 3:00 p.m. ET / 12:00 p.m. PT.
Sagimet Biosciences Inc. develops FASN inhibitors for diseases related to dysfunctional lipid metabolism. Their lead candidate, Denifanstat, shows promising results in treating nonalcoholic steatohepatitis and acne. The company has a strong safety profile and sufficient cash to last until 2025.
What type of business is Sagimet Biosciences - Seri?
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
What sector is Sagimet Biosciences - Seri in?
Sagimet Biosciences - Seri is in the Healthcare sector
What industry is Sagimet Biosciences - Seri in?
Sagimet Biosciences - Seri is in the Biotechnology industry
What country is Sagimet Biosciences - Seri from?
Sagimet Biosciences - Seri is headquartered in United States
When did Sagimet Biosciences - Seri go public?
Sagimet Biosciences - Seri initial public offering (IPO) was on 17 July 2023
What is Sagimet Biosciences - Seri website?
https://sagimet.com
Is Sagimet Biosciences - Seri in the S&P 500?
No, Sagimet Biosciences - Seri is not included in the S&P 500 index
Is Sagimet Biosciences - Seri in the NASDAQ 100?
No, Sagimet Biosciences - Seri is not included in the NASDAQ 100 index
Is Sagimet Biosciences - Seri in the Dow Jones?
No, Sagimet Biosciences - Seri is not included in the Dow Jones index
When does Sagimet Biosciences - Seri report earnings?
The next expected earnings date for Sagimet Biosciences - Seri is 21 August 2024